Feasibility Study of IV rtPA vs. Primary Endovascular Therapy for Acute Ischemic Stroke

  • Study type:

    Interventional What is this?

    Describes the nature of a clinical study. Types include:

    • Observational study — observes people and measures outcomes without affecting results.
    • Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
    • Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.

Study IDs

  • Site IRB:

    • Jacksonville, Florida: 12-002496
  • NCT ID:

    NCT01869478
  • Sponsor Protocol Number:

    12-002496

About this study

This pilot trial will be the first step toward direct comparison of delivery of endovascular reperfusion therapy to intravenous rt-PA in a time-to-treatment framework shown as most effective by the NINDS rt-PA Stroke Trial. A randomized trial is justified for the following reasons: 1) The high rate of death and disability associated with ischemic stroke despite treatment with intravenous rt-PA mandates critical analysis of alternate therapies with therapeutic potential, 2) endovascular treatment for acute ischemic stroke is expanding in North America without compelling evidence of safety and efficacy from well-designed clinical trials, 3) critical cost-effectiveness analysis cannot be done without acquiring pertinent outcomes data from controlled studies.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.

See eligibility criteria

Inclusion Criteria:

  • Age ≥ 18 years
  • Definite or probable ischemic stroke
  • CT angiographic (CTA) evidence of intracranial vascular occlusion (internal carotid, middle cerebral - M1 or M2 divisions, anterior cerebral, posterior cerebral, or basilar artery) within 3.5 hours of symptom onset
  • Able to receive assigned treatment within 4.5 hours of symptom onset
  • Written informed consent from patient or surrogate, if unable to provide consent

Exclusion Criteria:

  • CT evidence of early infarction in >1/3 of middle cerebral artery distribution
  • Blood pressure > 185/110 mmHg refractory to anti-hypertensive therapy
  • History of intracranial hemorrhage
  • History of ischemic stroke within past 3 months
  • History of major surgical procedure within past 14 days
  • Gastrointestinal or genitourinary bleeding within past 14 days
  • Glucose <50 or >400mg/dL
  • Platelet count <100,000
  • INR ≥ 1.7
  • Known history of bleeding diathesis

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Kevin Barrett, M.D.

Contact us for the latest status

Emily Edwards

(904)953-3035

Edwards.Emily@mayo.edu